ZA838058B - Controlled release theophylline tablets and a process for their preparation - Google Patents

Controlled release theophylline tablets and a process for their preparation

Info

Publication number
ZA838058B
ZA838058B ZA838058A ZA838058A ZA838058B ZA 838058 B ZA838058 B ZA 838058B ZA 838058 A ZA838058 A ZA 838058A ZA 838058 A ZA838058 A ZA 838058A ZA 838058 B ZA838058 B ZA 838058B
Authority
ZA
South Africa
Prior art keywords
weight
ratio
tablet
polymer
theophyllin
Prior art date
Application number
ZA838058A
Other languages
English (en)
Inventor
Joel Bougaret
Daniel Darbeau
Original Assignee
Fabre Sa Pierre
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fabre Sa Pierre filed Critical Fabre Sa Pierre
Publication of ZA838058B publication Critical patent/ZA838058B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
ZA838058A 1982-11-03 1983-10-28 Controlled release theophylline tablets and a process for their preparation ZA838058B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8218407A FR2535202B1 (fr) 1982-11-03 1982-11-03 Comprimes de theophylline a liberation controlee et leur procede de fabrication

Publications (1)

Publication Number Publication Date
ZA838058B true ZA838058B (en) 1984-06-27

Family

ID=9278859

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA838058A ZA838058B (en) 1982-11-03 1983-10-28 Controlled release theophylline tablets and a process for their preparation

Country Status (8)

Country Link
EP (1) EP0109320B1 (xx)
AT (1) ATE20517T1 (xx)
CA (1) CA1205385A (xx)
DE (1) DE3364276D1 (xx)
ES (1) ES526928A0 (xx)
FR (1) FR2535202B1 (xx)
PT (1) PT77581B (xx)
ZA (1) ZA838058B (xx)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA836031B (en) * 1983-08-16 1985-02-27 Verex Lab Constant release rate solid dosage theophylline formulation
FR2585948B1 (fr) * 1985-08-06 1988-12-16 Pf Medicament Procede de fabrication de comprimes d'indometacine
FR2588188B1 (fr) * 1985-10-04 1988-01-08 Delalande Sa Comprime de sel(s) hydrosoluble(s) de cinepazide a liberation programmee et son procede de preparation
GB8628728D0 (en) * 1986-12-02 1987-01-07 Euro Celtique Sa Spheroids
FR2618073B1 (fr) * 1987-07-16 1990-09-07 Pf Medicament Comprimes de type a matrice hydrophile a base de salbutamol et leur procede de preparation
GB8813064D0 (en) * 1988-06-02 1988-07-06 Euro Celtique Sa Controlled release dosage forms having defined water content
US5268181A (en) * 1989-04-13 1993-12-07 Upsher-Smith Laboratories, Inc. Method of using niacin to control nocturnal cholesterol synthesis
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6080428A (en) 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US6676967B1 (en) 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US5484607A (en) * 1993-10-13 1996-01-16 Horacek; H. Joseph Extended release clonidine formulation
US5393765A (en) * 1993-12-13 1995-02-28 Hoffmann-La Roche Inc. Pharmaceutical compositions with constant erosion volume for zero order controlled release
US6197340B1 (en) 1998-05-28 2001-03-06 Medical Research Institute Controlled release lipoic acid
WO2003011256A1 (en) * 2001-07-30 2003-02-13 Sun Pharmaceutical Industries Limited Oral controlled release pharmaceutical composition of a prokinetic agent
PT1888080E (pt) * 2005-06-09 2010-07-06 Euro Celtique Sa ComposiãŽes farmac—uticas de um esterëide neuroactivo e as suas utilizaãŽes
EP2155170A2 (en) 2007-06-08 2010-02-24 Addrenex Pharmaceuticals, Inc. Extended release formulation and method of treating adrenergic dysregulation
EP2937096B1 (en) 2014-04-23 2019-08-21 Julius-Maximilians-Universität Würzburg Peptides derived from RS1 which down-regulate glucose absorption after a glucose rich meal and increase insulin sensitivity

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2050701C3 (de) * 1969-10-17 1979-12-20 Shinetsu Chemical Co., Tokio Verwendung eines pulverförmigen Celluloseäthers als Hilfsstoff zur Herstellung von leicht zerfallbaren festen Arzneiformen
JPS4917565B1 (xx) * 1970-12-29 1974-05-01
AT347039B (de) * 1972-11-03 1978-12-11 Ohrenberger Franz X Dr Verfahren zur herstellung von tabletten und dragees mit einem gehalt an zwei verschiedenen heilmittelwirkstoffen mit verzoegerter wirk- stoffabgabe
JPS55153715A (en) * 1979-05-18 1980-11-29 Nikken Kagaku Kk Prolonged granule of theophylline
US4259314A (en) * 1979-12-10 1981-03-31 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals
JPS56122311A (en) * 1980-02-29 1981-09-25 Eisai Co Ltd Lasting theophylline pharmaceutical composition

Also Published As

Publication number Publication date
ES8405618A1 (es) 1984-07-01
PT77581B (fr) 1986-03-18
FR2535202B1 (fr) 1985-08-09
CA1205385A (fr) 1986-06-03
EP0109320A1 (fr) 1984-05-23
ATE20517T1 (de) 1986-07-15
EP0109320B1 (fr) 1986-06-25
DE3364276D1 (en) 1986-07-31
ES526928A0 (es) 1984-07-01
PT77581A (fr) 1983-11-01
FR2535202A1 (fr) 1984-05-04

Similar Documents

Publication Publication Date Title
ZA838058B (en) Controlled release theophylline tablets and a process for their preparation
AU616449B2 (en) Controlled release combination of carbidopa/levodopa
US4900755A (en) Controlled release combination of carbidopa/levodopa
EP0253490B1 (en) Controlled release combination of carbidopa/levodopa
NO149490B (no) Fremgangsmaate ved fremstilling av tabletter med regulert frigjoerelse av den aktive bestanddel
AU7643591A (en) A pharmaceutical preparation
CA2093806A1 (en) Method of treating or preventing type 1 diabetes by oral administration of insulin
PT79054A (en) Process for the preparation of a controlled-release medicament delivery composition using crosslinked porous polymers
CA2041774A1 (en) Use of cross-linked amylose as a matrix for the slow release of biologically active compounds
ATE196081T1 (de) L-dopa ester enthaltende zusammensetzung
PT85591A (en) Process for the preparation of multiple unit dosage pharmaceutical compositions comprising as a pharmaceutilly active compound l-dopa
GR3006498T3 (xx)
EP0348688B1 (en) Solid pharmaceutical preparation and method of producing same
OA08018A (fr) Matrice inerte à base de polycaprolactone pour administration orale d'un médicament, et procédé de préparation de la forme galénique comprenant cette matrice.
EP0374096A1 (de) 2',3'-Dideoxypurinnucleosid/Purinnucleosid-Phosphorylase-Inhibitor Kombinationstherapie und Zusammensetzungen dafür
CH660303A5 (de) Analgetische praeparate.
ES2059260A1 (es) Procedimiento de preparacion de comprimidos conteniendo diclofenaco; dispersables en agua.
JPS5921615A (ja) 鎮痛剤組成物
DE2823268C2 (xx)
DE1617418C3 (de) Herstellung von festen Arzneimittelformen mit verzögerter Wirkstoffabgabe
US3758680A (en) Composition of matter and method of use
EP0018550A2 (de) Mittel zur Behandlung von Muskelerkrankungen
DE2743702A1 (de) Abmagerungs- oder schlankmacher- zubereitung und verfahren zu ihrer herstellung
EP3335700A1 (de) Feste pharmazeutische orale darreichungsform mit verlängerter wirkstofffreisetzung umfassend mirabegron
US3642993A (en) Pharmaceutical composition containing 2-methyl - 5 - phenyl - 1 2-dihydro-3h-2-benzazepine for treatment of a condition associated with anxiety or tension